◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › I › INCY

Incyte Corporation (INCY) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Biotechnology · DATA UPDATED 2026-09-19

Incyte Corporation (INCY) operates in the Biotechnology industry and is headquartered in Wilmington, United States with about 2,844 employees. Its market capitalization is roughly $25 billion. In the fiscal year ended 2025-12-31, INCY reported $5.1B in revenue and $1.3B in net income.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

Interactive charts & full statements → Open the INCY valuation workbench →

INCY Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$5.8B	$5.1B	$4.2B	$3.7B	$3.4B	$3.0B	$2.7B	$2.2B	$1.9B	$1.5B	$1.1B	$754M	$511M	$355M	$297M	$94M	$170M	$9M	$4M	$34M	$28M
Gross Profit	$5.4B	$4.8B	$3.9B	$3.4B	$3.2B	$2.8B	$2.5B	$2.0B	$1.8B	$1.5B	$1.0B	$727M	$508M	$354M	$297M	$94M	$170M	$9M	$4M	$34M	$28M
Gross Margin %	92.6%	92.8%	92.6%	93.1%	93.9%	94.9%	95.1%	94.7%	95.0%	94.8%	94.7%	96.4%	99.4%	99.8%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	$1.8B	$1.3B	$101M	$655M	$592M	$586M	($264M)	$402M	$129M	($243M)	$145M	$51M	($5M)	($16M)	$1M	($143M)	$14M	($140M)	($159M)	($85M)	($77M)
Operating Margin %	31.6%	26.1%	2.4%	17.7%	17.4%	19.6%	-9.9%	18.6%	6.9%	-15.8%	13.1%	6.7%	-0.9%	-4.5%	0.4%	-151.6%	8.3%	-1508.6%	-4064.5%	-247.6%	-278.1%
Net Income	$1.6B	$1.3B	$33M	$598M	$341M	$949M	($296M)	$447M	$109M	($313M)	$104M	$7M	($48M)	($83M)	($44M)	($187M)	($32M)	($212M)	($179M)	($87M)	($74M)
Net Margin %	27.7%	25.0%	0.8%	16.2%	10.0%	31.8%	-11.1%	20.7%	5.8%	-20.4%	9.4%	0.9%	-9.5%	-23.4%	-14.9%	-197.5%	-18.8%	-2286.8%	-4565.4%	-252.3%	-268.3%
EBITDA	—	$1.8B	$408M	$919M	$600M	$630M	($178M)	$543M	$172M	($253M)	$205M	$98M	$40M	($15M)	$32M	($116M)	$36M	($123M)	($146M)	($72M)	($69M)
Earnings Per Share (EPS)	$7.85	$6.41	$0.15	$2.65	$1.52	$4.27	$-1.36	$2.05	$0.51	$-1.53	$0.54	$0.03	$-0.29	$-0.56	$-0.34	$-1.49	$-0.26	$-2.06	$-1.99	$-1.03	$-0.89
Shares Outstanding (M)	—	201M	211M	226M	224M	222M	218M	218M	216M	205M	194M	187M	168M	148M	130M	125M	122M	103M	90M	84M	84M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INCY Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$1.7B	$1.3B	$1.5B	$1.4B	$1.2B	$1.1B	$1.2B	$1.1B	$1.0B
Gross Profit	$1.6B	$1.2B	$1.4B	$1.3B	$1.1B	$980M	$1.1B	$1.1B	$967M
Gross Margin %	93.7%	91.8%	92.0%	92.8%	93.5%	93.0%	92.5%	92.4%	92.7%
Operating Income (EBIT)	$700M	$324M	$384M	$431M	$311M	$217M	$297M	$146M	($478M)
Operating Margin %	41.8%	25.5%	25.5%	31.6%	25.6%	20.6%	25.2%	12.8%	-45.8%
Net Income	$586M	$303M	$299M	$424M	$405M	$158M	$201M	$106M	($445M)
Net Margin %	35.0%	23.8%	19.9%	31.1%	33.3%	15.0%	17.1%	9.4%	-42.6%
EBITDA	—	$368M	$415M	$507M	$582M	$257M	$337M	$180M	($367M)
Earnings Per Share (EPS)	$2.81	$1.47	$1.46	$2.11	$2.04	$0.80	$1.02	$0.54	$-2.04
Shares Outstanding (M)	—	207M	205M	201M	199M	198M	197M	196M	218M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INCY Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$2.0B	$1.4B	$335M	$496M	$970M	$749M	($125M)	$711M	$336M	($93M)	$305M	$87M	$26M	$9M	($95M)	($162M)	$98M	$12M	($141M)	($93M)	($50M)
Capital Expenditures (CapEx)	—	$59M	$86M	$47M	$78M	$181M	$187M	$78M	$73M	$111M	$120M	$26M	$28M	$4M	$3M	$4M	$4M	$0M	$1M	$1M	$2M
Free Cash Flow (FCF)	$1.9B	$1.4B	$249M	$449M	$892M	$568M	($312M)	$633M	$263M	($204M)	$184M	$61M	($2M)	$5M	($98M)	($166M)	$94M	$12M	($142M)	($94M)	($52M)
FCF Margin %	33.0%	26.4%	5.9%	12.2%	26.3%	19.0%	-11.7%	29.3%	14.0%	-13.3%	16.7%	8.0%	-0.3%	1.4%	-32.9%	-175.2%	55.2%	129.2%	-3612.1%	-272.5%	-187.9%
Dividends Paid	—	—	—	—	$26M	$30M	$23M	$17M	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INCY Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$508M	$369M	$543M	$559M	$45M	$266M	$381M	$311M	($576M)
Capital Expenditures (CapEx)	—	$10M	$22M	$15M	$19M	$3M	$17M	$18M	$56M
Free Cash Flow (FCF)	$495M	$359M	$521M	$545M	$26M	$263M	$364M	$293M	($631M)
FCF Margin %	29.6%	28.2%	34.6%	39.9%	2.1%	25.0%	30.9%	25.8%	-60.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INCY Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$7.9B	$7.0B	$5.4B	$6.8B	$5.8B	$4.9B	$3.6B	$3.4B	$2.6B	$2.3B	$1.6B	$1.0B	$830M	$630M	$330M	$329M	$490M	$712M	$232M	$276M	$354M
Cash & Cash Equivalents	$4.0B	$3.1B	$1.7B	$3.2B	$3.0B	$2.1B	$1.5B	$1.8B	$1.2B	$900M	$652M	$521M	$452M	$471M	$224M	$278M	$418M	$450M	$179M	$109M	$19M
Total Liabilities	$1.5B	$1.8B	$2.0B	$1.6B	$1.5B	$1.2B	$950M	$828M	$720M	$672M	$1.2B	$836M	$878M	$823M	$505M	$556M	$578M	$815M	$453M	$435M	$439M
Total Debt (Short + Long-Term)	—	$10M	$44M	$38M	$41M	$45M	$15M	$47M	$36M	$24M	$1.3B	$1.2B	$689M	$662M	$331M	$614M	$293M	$443M	$425M	$409M	$387M
Total Shareholders' Equity	$6.3B	$5.2B	$3.4B	$5.2B	$4.4B	$3.8B	$2.6B	$2.6B	$1.9B	$1.6B	$419M	$171M	($82M)	($193M)	($175M)	($227M)	($89M)	($102M)	($221M)	($160M)	($85M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INCY viewer.

INCY Metric Deep Dives

Other Companies in Biotechnology

BIIB · Biogen — $32 billion
2315 · Biocytogen Pharmaceuticals (Beijing) Co., Ltd. — HK$27 billion
DCAL · Dishman Carbogen Amcis Limited — ₹27 billion
9969 · InnoCare Pharma Limited — HK$26 billion
4875 · MediciNova, Inc. — JPY 24 billion
PANACEABIO · Panacea Biotec Limited — ₹23 billion
9688 · Zai Lab Limited — HK$22 billion
2162 · Keymed Biosciences Inc. — HK$21 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← INCU All “I” companies IND →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.